Filing Flows › Comparisons › PROF vs IDXG
Profound Medical vs Interpace Biosciences: PROF and IDXG compared
Profound Medical is the larger company: $9.8M of revenue in its latest quarter (Q3 2026) against $9.1M for Interpace Biosciences (Q2 2026). Profound Medical is growing faster (+86% against -1% a year earlier). Interpace Biosciences is more profitable, with an operating margin of 3.5% against -79.6%.
Where the money goes: PROF and IDXG
Profound Medical (PROF) · Q3 2026
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
Interpace Biosciences (IDXG) · Q2 2026
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
| Profound Medical (PROF) | Interpace Biosciences (IDXG) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $9.8M | $9.1M |
| Revenue growth, Y/Y | +86% | -1% |
| Gross margin | — | 61.9% |
| Operating margin | -79.6% | 3.5% |
| Net earnings | −$7.7M | $158K |
| Net margin | -78.6% | 1.7% |
| Operating cash flow | −$5.0M | $98K |
| Free cash flow | — | $41K |
| Market value | $264M | — |
| Analysts’ mean target | $11.14 | — |
Where the revenue comes from
Profound Medical
- Capital equipment: $5.7M (58%)
- Recurring - non-capital: $4.1M (42%)
Questions
Which is bigger, Profound Medical or Interpace Biosciences?
Profound Medical is the larger company: $9.8M of revenue in its latest quarter (Q3 2026) against $9.1M for Interpace Biosciences (Q2 2026).
Is Profound Medical or Interpace Biosciences growing faster?
Profound Medical is growing faster (+86% against -1% a year earlier).
Which is more profitable, Profound Medical or Interpace Biosciences?
Interpace Biosciences is more profitable, with an operating margin of 3.5% against -79.6%.
More: Profound Medical earnings · how Profound Medical makes money · Interpace Biosciences earnings · how Interpace Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.